Charles Schwab’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-565,578
| Closed | -$1.92M | – | 3160 |
|
|
2018
Q3 | $1.92M | Buy |
565,578
+15,854
| +3% | +$57.2K | ﹤0.01% | 2435 |
|
|
2018
Q2 | $2.07M | Buy |
549,724
+12,773
| +2% | +$62.2K | ﹤0.01% | 2369 |
|
|
2018
Q1 | $2.2M | Buy |
536,951
+17,620
| +3% | +$82K | ﹤0.01% | 2300 |
|
|
2017
Q4 | $2.42M | Buy |
519,331
+23,435
| +5% | +$129K | ﹤0.01% | 2245 |
|
|
2017
Q3 | $3.52M | Buy |
495,896
+54,790
| +12% | +$394K | ﹤0.01% | 2060 |
|
|
2017
Q2 | $3.19M | Buy |
441,106
+4,388
| +1% | +$27.4K | ﹤0.01% | 2040 |
|
|
2017
Q1 | $2.69M | Buy |
436,718
+25,842
| +6% | +$142K | ﹤0.01% | 2085 |
|
|
2016
Q4 | $2.41M | Buy |
410,876
+24,133
| +6% | +$132K | ﹤0.01% | 2097 |
|
|
2016
Q3 | $2.05M | Buy |
386,743
+20,192
| +6% | +$109K | ﹤0.01% | 2117 |
|
|
2016
Q2 | $2.43M | Sell |
366,551
-18,276
| -5% | -$102K | ﹤0.01% | 1966 |
|
|
2016
Q1 | $1.8M | Buy |
384,827
+9,172
| +2% | +$36.6K | ﹤0.01% | 2108 |
|
|
2015
Q4 | $1.9M | Buy |
375,655
+13,405
| +4% | +$63.7K | ﹤0.01% | 2108 |
|
|
2015
Q3 | $1.28M | Buy |
362,250
+51,567
| +17% | +$345K | ﹤0.01% | 2291 |
|
|
2015
Q2 | $3.1M | Buy |
310,683
+9,530
| +3% | +$102K | ﹤0.01% | 1852 |
|
|
2015
Q1 | $3.83M | Buy |
301,153
+41,205
| +16% | +$530K | 0.01% | 1691 |
|
|
2014
Q4 | $3.68M | Buy |
259,948
+7,811
| +3% | +$121K | 0.01% | 1663 |
|
|
2014
Q3 | $3.47M | Buy |
252,137
+22,539
| +10% | +$345K | 0.01% | 1648 |
|
|
2014
Q2 | $3.53M | Sell |
229,598
-1,116
| -0.5% | -$15.8K | 0.01% | 1646 |
|
|
2014
Q1 | $3.93M | Buy |
230,714
+41,404
| +22% | +$625K | 0.01% | 1526 |
|
|
2013
Q4 | $2.45M | Buy |
189,310
+15,224
| +9% | +$182K | ﹤0.01% | 1783 |
|
|
2013
Q3 | $1.81M | Buy |
174,086
+5,168
| +3% | +$46K | ﹤0.01% | 1908 |
|
|
2013
Q2 | $1.33M | Buy |
+168,918
| New | +$1.32M | ﹤0.01% | 1988 |
|
Charles Schwab's KERX Position: Q4 2018 in Review
Charles Schwab sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 565,578 shares — an estimated $1.92M sold.
Charles Schwab first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $3.93M in Q1 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Charles Schwab reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Charles Schwab sold 565,578 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $1.92M.
- Charles Schwab first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Charles Schwab's Keryx Biopharmaceuticals Inc position peaked at $3.93M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Charles Schwab's 13F filing for Q4 2018, filed 14 Feb 2019.